品牌 | 其他品牌 | 货号 | BFN60808823 |
---|---|---|---|
规格 | T25培养瓶x1 1.5ml冻存管x2 | 供货周期 | 现货 |
主要用途 | 仅供科研 | 应用领域 | 医疗卫生,生物产业 |
细胞名称 | 人肝内胆管癌细胞HuCCT-1 | ||
货物编码 | BFN60808823 | ||
产品规格 | T25培养瓶x1 | 1.5ml冻存管x2 | |
细胞数量 | 1x10^6 | 1x10^6 | |
保存温度 | 37℃ | -198℃ | |
运输方式 | 常温保温运输 | 干冰运输 | |
安全等级 | 1 | ||
用途限制 | 仅供科研 3类 |
培养体系 | 90%DMEM+10%FBS+1%三抗 | ||
培养温度 | 37℃ | 二氧化碳浓度 | 5% |
简介 | 人肝内胆管癌细胞HuCCT-1取自56岁男性供体。该细胞源于JCRB | ||
注释 | Part of: Cancer Cell Line Encyclopedia (CCLE) project. Part of: COSMIC cell lines project. Part of: TCGA-110-CL cell line panel. Doubling time: ~55 hours (at 10th passage in RPMI + 10% FBS), ~74 hours (at 25th passage in RPMI + 0.2% LA) (PubMed=2544546). Microsatellite instability: Stable (MSS) (Sanger). Omics: Deep exome analysis. Omics: Deep RNAseq analysis. Omics: DNA methylation analysis. Omics: SNP array analysis. Omics: Transcriptome analysis. | ||
基因突变 | Heterozygous for KRAS p.Gly12Asp (c.35G>A) (ClinVar=VCV000012582) (CCLE; Cosmic-CLP). Heterozygous for MSH6 p.Lys1358fs*2 (c.4071_4072insGATT) (CCLE; Cosmic-CLP). Homozygous for TP53 p.Arg175His (c.524G>A) (ClinVar=VCV000012374) (CCLE; Cosmic-CLP). | ||
HLA信息 | / | ||
STR信息 |
Amelogenin X,Y CSF1PO 11,12 D2S1338 17,18 D3S1358 15 D5S818 12,13 D7S820 10,11 D8S1179 10 D13S317 11,13 D16S539 11,12 (Cosmic-CLP; JCRB; RCB; TKG) 9,11,12 (PubMed=25877200) D18S51 13 D19S433 13 D21S11 31 FGA 20,23 Penta D 10 Penta E 15,18 TH01 7,10 TPOX 8 vWA 18 | ||
参考文献 | PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747 Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019)
PubMed=31068700; DOI=10.1038/s41586-019-1186-3 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019)
PubMed=31077409; DOI=10.1002/hep.30704 Sittithumcharee G., Suppramote O., Vaeteewoottacharn K., Sirisuksakun C., Jamnongsong S., Laphanuwat P., Suntiparpluacha M., Matha A., Chusorn P., Buraphat P., Kakanaporn C., Charngkaew K., Silsirivanit A., Korphaisarn K., Limsrichamrern S., Tripatara P., Pairojkul C., Wongkham S., Sampattavanich S., Okada S., Jirawatnotai S. Dependency of cholangiocarcinoma on cyclin D-dependent kinase activity. Hepatology 70:1614-1630(2019)
PubMed=31395879; DOI=10.1038/s41467-019-11415-2 Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M. Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types. Nat. Commun. 10:3574-3574(2019) |